Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Q3 2023 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Nov 02, 2023 / 12:30PM GMT
Release Date Price: €7 (+5.26%)
Operator

Greetings. Welcome to Aurinia Pharmaceuticals Third Quarter 2023 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Jamie Harrell, Investor Relations for Aurinia Pharmaceuticals. Thank you. You may begin.

James Archie Harrell
Aurinia Pharmaceuticals Inc. - Head of IR

Thank you, operator, and thank you to everyone for joining today's call and webcast to review and discuss Aurinia's Third quarter and 9 months 2023 Financial and Operational Results. Joining me on the call this morning are Peter Greenleaf, Chief Executive Officer; and Joe Miller, our Chief Financial Officer. This morning, Aurinia issued a press release announcing its financial results and operational highlights for the third quarter and 9 months that ended September 30, 2023. In addition, the company filed its quarterly financial statements on Form 10-Q.

For more information, please refer to Aurinia's filings with the U.S. Securities and Exchange Commission, which are also available on Aurinia

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot